All News

Advate for prevention and control of bleeding in people with hemophilia A.

Oncologists will soon be able to offer patients the first 5-HT3 receptor antagonist with an indication for delayed chemotherapy-induced nausea and vomiting (CINV). The FDA recently approved palonosetron (Aloxi, MGI Pharma/Helsinn Healthcare) injection for the prevention of acute nausea and vomiting associated with initial and repeat courses of moderately and highly emetogenic cancer chemotherapy and the prevention of delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy. Palonosetron will be available to patients within the next several weeks.

What happens when a patient can't pay for his Rxs?

Here's how to get more R.Ph.s to use their prescriptive authority, allowed in most states but lagging in practice

Three state pharmacy boards are adopting an on-line pharmacist licensure renewal program developed by the National Association of Boards of Pharmacy.

PhRMA supports requiring drugs to be pedigreed to prevent counterfeiting, while HDMA thinks there other ways to get this done

How do R.Ph.s feel about PBMs and other third-party payers they have to deal with day in and day out? Find out in this exclusive Drug Topics survey

Two drug error case studies are presented

JCAHO tightens screws on its infection control standards

Public Citizen urges feds to regulate patient package inserts, while pharmacy groups argue that they should be left up to industry to take care of.

The American Foundation for Pharmaceutical Education launched a campaign to help recruit more pharmacists to teaching using grants totaling $12 million to fund fellowships for pharmacy faculty positions.

The frustration of waiting for callbacks

The amber vial is contributing to patient noncompliance with their drug regimen.

Columbia Laboratories' Striant for men with testosterone deficiency is delivered buccally.

Pharmacists in Maine agree with concept of a drug discount program, but are suspicious of the program's details.

Many states are applying for a waiver under the Pharmacy Plus program in order to obtain funds for a non-Medicaid seniors' drug program, but there is a long-term risk involved.

Men with benign prostatic hyperplasia (BPH) will soon have a therapeutic option that uses a unique drug delivery system. The FDA recently approved alfuzosin (UroXatral, Sanofi-Synthelabo) extended-release tablets for the treatment of the signs and symptoms of BPH. Alfuzosin is not indicated for the treatment of hypertension. The manufacturer expects alfuzosin to be available in pharmacies sometime in the second half of 2003.

Striant - testosterone buccal system

Clinicians can now offer their patients with non-Hodgkin?s lymphoma (NHL) therapy that combines targeted radiation with patient-specific dosing. The FDA recently approved tositumomab and iodine I-131 tositumomab (Bexxar, Corixa Corporation/GlaxoSmithKline) for the treatment of patients with CD20-positive, follicular NHL, with and without transformation, whose disease is refractory to rituxamab (Rituxan, Genentech) and has relapsed following chemotherapy. Training can be requested and orders placed by calling (877) 423-9927. Corixa recently began supplying Bexxar to cancer treatment centers.

The amber vial is contributing to patient noncompliance with their drug regimen.

Columbia Laboratories' Striant for men with testosterone deficiency is delivered buccally.

Provisions under House and Senate versions of prescription drug benefits legislation and their impact on FDA final rules regarding generic drug approvals under the Waxman-Hatch Act.

Pharmacy benefit managers are pushing incentive programs.

Interview with Kathleen Jaeger, President of GPhA.

Provisions under House and Senate versions of prescription drug benefits legislation and their impact on FDA final rules regarding generic drug approvals under the Waxman-Hatch Act.

Generic drug use playing larger role in contract negotiations for health benefits with unions.

Generic biologics

2003 is turning out to be a positive year for generic drug approvals.